Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Recruiting
Phase 1
Phase 2
Interventional Study
Cancer
Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (Locally Advanced or Metastatic)
Prostate Cancer - Recurrent
Pancreatic Ductal Adenocarcinoma (PDAC)
Ovarian Cancer
Glioblastoma
Melanoma (Skin Cancer)
Acute Myeloid Leukemia (AML)
Non Hodgkin Lymphoma
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Liver Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 8 – 85
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 85 (estimated)
- Sponsor
- Essen Biotech · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen p…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18-75 years.
* Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumor that is relapsed/refractory after standard therapy, or no standard therapy available.
* Targetable antigen positivity from the protocol target menu based on:
tissue bi…
Contacts